Affinage

LPXN

Leupaxin · UniProt O60711

Length
386 aa
Mass
43.3 kDa
Annotated
2026-06-10
39 papers in source corpus 18 papers cited in narrative 18 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/8 claims corpus-supported (88%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

LPXN (leupaxin) is a paxillin-family adaptor protein that scaffolds tyrosine-kinase signaling complexes at podosomes and focal adhesions to control cell adhesion, migration, and cytoskeletal dynamics (PMID:17329398, PMID:16914530). It assembles a complex with the kinases Pyk2 and c-Src and the phosphatase PTP-PEST, which tunes Pyk2/Src association and downstream Rho GTPase activity and migratory behavior (PMID:17329398, PMID:16914530). Its LIM3 domain is the principal focal-adhesion targeting module, and GPCR (bombesin/GRPr) stimulation drives LPXN translocation from the cytoplasm to focal adhesions where it is tyrosine-phosphorylated at Y22, Y62, and Y72; focal-adhesion localization is required for, but is upstream of, this phosphorylation (PMID:20543562). In B cells, Lyn binds the LD3 region and phosphorylates LPXN exclusively at Tyr72, and this modification is required for LPXN to suppress BCR-induced JNK, p38, and Akt signaling (PMID:17640867). Structurally, Kindlin-3 directly engages LPXN through residues G43/L47 in its F0 domain, and this interaction restrains myeloid-cell spreading, motility, mesenchymal-to-amoeboid transition, and phagocytosis (PMID:32094207). In cancer, LPXN promotes invasion and metastasis through multiple convergent routes: it recruits ERK to phosphorylate caldesmon and weaken its actin association (PMID:26079947), downregulates p120-catenin to drive nuclear beta-catenin accumulation and MMP-7 transcription (PMID:19701244), and integrates collagen mechanical cues with the actin cytoskeleton via paxillin under negative control by the HLF transcription factor (PMID:40473600). Beyond adhesion, LPXN moonlights in metabolism, stabilizing the lipid-droplet protein CIDEC by blocking its ubiquitin-proteasomal degradation to promote adipocyte lipid storage (PMID:38159847), and acting as a nuclear coactivator that binds HNF4alpha and the PEPCK promoter to drive hepatic gluconeogenesis through the Gcg-cAMP-PKA pathway (PMID:39603504). LPXN is recurrently involved in AML through RUNX1 and ETV6 gene fusions and through Pyk2-driven signaling in FLT3-mutant leukemic stem cells (PMID:19760607, PMID:26542893, PMID:36056084).

Mechanistic history

Synthesis pass · year-by-year structured walk · 18 steps
  1. 2006 Medium

    Established that LPXN functions as a scaffold for a podosomal kinase/phosphatase complex, addressing what role this paxillin homolog plays in bone-resorbing cells.

    Evidence Co-IP screen and resorption/adhesion assays with adenoviral overexpression in murine osteoclasts

    PMID:16914530

    Open questions at the time
    • Did not map the domains mediating Pyk2/Src/PTP-PEST assembly
    • Direct vs indirect nature of each interaction not resolved
  2. 2007 Medium

    Defined the LPXN-Pyk2-Src-PTP-PEST complex as a migration regulator in cancer and showed PTP-PEST antagonizes complex assembly, linking LPXN to Rho GTPase output.

    Evidence Reciprocal Co-IP, siRNA knockdown, overexpression, Transwell migration and Rho GTPase activity assays in PC-3 cells

    PMID:17329398

    Open questions at the time
    • Mechanism by which PTP-PEST displaces Pyk2/Src from LPXN unresolved
    • Which Rho GTPase effector pathway is engaged not defined
  3. 2007 High

    Identified LPXN as a negative regulator of BCR signaling, mapping Lyn binding to LD3 and the single required phosphosite Tyr72.

    Evidence Domain-deletion and site-directed mutagenesis (Y72F), kinase assay, Co-IP and IL-2 ELISA in A20 B lymphoma cells

    PMID:17640867

    Open questions at the time
    • Downstream effectors connecting pTyr72-LPXN to JNK/p38/Akt suppression not identified
    • Selectivity for JNK/p38/Akt over ERK/NFkB unexplained
  4. 2009 Medium

    Connected LPXN to AML pathogenesis via a RUNX1 fusion and showed both wild-type and fusion proteins are transforming, while RUNX1/LPXN sequesters CBFB and represses CSF1R transactivation.

    Evidence Localization microscopy, CSF1R luciferase reporter, CBFB Co-IP, soft agar and xenograft assays in NIH3T3

    PMID:19760607

    Open questions at the time
    • Mechanism of wild-type LPXN transformation not dissected
    • Patient-level recurrence of the fusion not established
  5. 2009 High

    Demonstrated in vivo that LPXN drives prostate cancer metastasis via p120-catenin downregulation, nuclear beta-catenin accumulation, and MMP-7 induction.

    Evidence LPXN/TRAMP double-transgenic mice, siRNA, immunofluorescence, MMP-7 reporter and invasion assays

    PMID:19701244

    Open questions at the time
    • Molecular link between LPXN and p120-catenin downregulation not identified
    • Whether nuclear LPXN itself participates not addressed here
  6. 2010 High

    Mapped LIM3 as the focal-adhesion targeting domain and ordered the events: FA localization precedes and is required for GPCR-stimulated Tyr phosphorylation, while LPXN opposes paxillin in collagen adhesion.

    Evidence LIM3 and Y22/62/72F mutagenesis, siRNA, live-cell imaging, adhesion and spreading assays with bombesin stimulation

    PMID:20543562

    Open questions at the time
    • Identity of the FA receptor/anchor for LIM3 unknown
    • Substrate basis for opposite LPXN/paxillin adhesion roles unclear
  7. 2015 Medium

    Defined a TAK1-LPXN-ERK-caldesmon axis whereby LPXN recruits ERK to phosphorylate caldesmon, weakening its actin affinity to enable motility.

    Evidence Co-IP, siRNA, antibody array, migration/invasion assays in prostate cancer cells

    PMID:26079947

    Open questions at the time
    • Direct vs scaffolded ERK-caldesmon phosphorylation not separated
    • TAK1 placement upstream is correlative
  8. 2015 Medium

    Showed an ETV6-LPXN fusion in relapsing AML enhances G-CSF-driven proliferation and CXCL12 chemotaxis without blocking differentiation.

    Evidence 3'-RACE, FISH, retroviral 32D transduction, proliferation and CXCL12 Transwell assays

    PMID:26542893

    Open questions at the time
    • Which LPXN domains the fusion retains for function not dissected
    • No in vivo leukemogenesis test of the fusion
  9. 2017 Low

    Reported that LPXN overexpression promotes monocytic leukemia proliferation, integrin-mediated fibronectin adhesion, and MMP-2-driven invasion.

    Evidence Lentiviral overexpression, proliferation/adhesion/invasion assays, western blot, zymography in THP-1 cells

    PMID:28641616

    Open questions at the time
    • Overexpression only without rescue or mutagenesis
    • Direct vs indirect regulation of integrins and MMP-2 unestablished
  10. 2018 Low

    Placed LPXN upstream of JNK/p38 MAPK and MMP-2/9 in monocytic leukemia invasion, while finding ERK unaffected, contrasting with prior contexts.

    Evidence siRNA, proliferation/invasion assays, western blot, zymography in SHI-1 cells

    PMID:30655748

    Open questions at the time
    • Single knockdown approach without rescue
    • Context-dependent ERK independence unexplained
  11. 2018 Low

    Linked LPXN to bladder cancer proliferation, invasion, and angiogenesis through PI3K/AKT-dependent S100P upregulation.

    Evidence Overexpression/knockdown, PI3K/AKT inhibitor, western blot, in vitro and in vivo assays

    PMID:29975926

    Open questions at the time
    • No direct binding or epistasis placing LPXN in PI3K/AKT
    • S100P as direct vs indirect target not resolved
  12. 2020 High

    Provided a structural basis for LPXN regulation by myeloid cells, showing Kindlin-3 directly binds LPXN via F0 G43/L47 to restrain macrophage motility and phagocytosis.

    Evidence NMR spectroscopy, G43/L47 mutagenesis, macrophage spreading/migration/phagocytosis assays vs Kindlin-3 knockout

    PMID:32094207

    Open questions at the time
    • Which LPXN surface contacts Kindlin-3 not mapped
    • How this link integrates with the Pyk2/Src complex unknown
  13. 2020 Medium

    Tested the in vivo requirement for Lpxn in B-cell immunity, revealing it is dispensable for antibody responses despite an in vitro plasma-cell differentiation defect.

    Evidence Lpxn knockout mice, in vitro differentiation, T-dependent/independent immunization, antibody ELISA

    PMID:32269569

    Open questions at the time
    • Redundancy with paxillin/Hic-5 in vivo not tested
    • Reconciliation with cell-intrinsic BCR-suppressive role unresolved
  14. 2022 Medium

    Connected LPXN to therapy resistance, showing Pyk2 (PTK2B) phosphorylates LPXN during FLT3-TKI resistance and that both are enriched in leukemic stem cells.

    Evidence Multilayered/nascent proteomics, PTK2B/FAK inhibition, xenograft, migration assays

    PMID:36056084

    Open questions at the time
    • LPXN phosphosites in this context not mapped
    • Causal contribution of LPXN phosphorylation to resistance not isolated
  15. 2023 Medium

    Revealed a non-adhesion metabolic function: LPXN stabilizes CIDEC by inhibiting its ubiquitin-proteasomal degradation to promote lipid storage, independent of FAK and TAG synthesis.

    Evidence HTRF screen, Co-IP, ubiquitination assay, proteasome inhibition, lipid droplet imaging in adipocytes

    PMID:38159847

    Open questions at the time
    • How LPXN shields CIDEC from the ubiquitin machinery mechanistically unclear
    • Which E3 ligase LPXN antagonizes not identified
  16. 2024 High

    Established LPXN as a nuclear coactivator for HNF4alpha that binds the PEPCK promoter to drive hepatic gluconeogenesis, defining a transcriptional/metabolic role distinct from focal adhesions.

    Evidence Pull-down/MS, luciferase reporter, CUT&Tag, ChIP-qPCR, in vivo AAV/adenoviral manipulation in ob/db/DIO mice and hepatocytes

    PMID:39603504

    Open questions at the time
    • Signal triggering LPXN nuclear translocation in hepatocytes unknown
    • How adhesion-associated phosphorylation relates to nuclear function unresolved
  17. 2025 Medium

    Positioned LPXN downstream of HLF/BRG1 epigenetic control as a mediator that couples collagen mechanical cues to the actin cytoskeleton via paxillin to drive metastasis.

    Evidence In vivo CRISPR-Cas9 screen, HLF/LPXN overexpression and knockdown, collagen migration assay, lung metastasis xenografts

    PMID:40473600

    Open questions at the time
    • Direct LPXN-paxillin mechanochemical coupling not biochemically reconstituted
    • Whether HLF regulates LPXN directly not established
  18. 2025 Low

    Proposed an immunomodulatory route in which LPXN promotes M2 macrophage polarization through an HDAC6/EGR2 deacetylation axis to support breast cancer progression.

    Evidence siRNA, co-culture, Co-IP (HDAC6-EGR2), HDAC6 inhibitor, murine breast cancer model

    PMID:41286384

    Open questions at the time
    • Full axis not reconstituted biochemically; relies on sequential knockdown/inhibitor
    • Direct LPXN-HDAC6 link not demonstrated

Open questions

Synthesis pass · forward-looking unresolved questions
  • It remains unknown how LPXN's signal-dependent partitioning between focal adhesions and the nucleus is controlled and whether its adhesion-associated phosphorylation governs its transcriptional and metabolic functions.
  • No unifying mechanism linking FA phosphorylation to nuclear coactivator activity
  • No structural model of the full-length protein in distinct compartments
  • Tissue-specific partner switching not mapped

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0060090 molecular adaptor activity 3 GO:0008092 cytoskeletal protein binding 2 GO:0098772 molecular function regulator activity 2 GO:0140110 transcription regulator activity 2
Localization
GO:0005634 nucleus 2 GO:0005811 lipid droplet 1 GO:0005829 cytosol 1
Pathway
R-HSA-162582 Signal Transduction 3 R-HSA-1643685 Disease 3 R-HSA-168256 Immune System 3 R-HSA-1430728 Metabolism 2 R-HSA-1474244 Extracellular matrix organization 2 R-HSA-74160 Gene expression (Transcription) 1
Partners
CIDECFERMT3HNF4ALYNPTK2BPTPN12PXNSRC
Complex memberships
Pyk2-Src-PTP-PEST podosomal/focal adhesion complex

Evidence

Reading pass · 18 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2007 LPXN associates with Pyk2, c-Src, and PTP-PEST in prostate cancer (PC-3) cells to form a signaling complex that regulates cell migration; siRNA-mediated knockdown of LPXN decreased PC-3 migration, overexpression of LPXN increased Rho GTPase activity and migration, and overexpression of PTP-PEST decreased Pyk2/c-Src association with LPXN and reduced migration. Co-immunoprecipitation, siRNA knockdown, adenoviral overexpression, in vitro Transwell migration assay, Rho GTPase activity assay American journal of physiology. Cell physiology Medium 17329398
2007 LPXN is tyrosine-phosphorylated by Lyn exclusively at Tyr72 (adjacent to the LD3 domain) upon BCR stimulation in B cells; LPXN's LD3 domain mediates binding to Lyn; LPXN overexpression suppresses BCR-induced JNK, p38 MAPK, and Akt activation but not ERK or NFκB, and suppresses IL-2 secretion; the Y72F mutant abrogates this inhibitory function, demonstrating Tyr72 phosphorylation is required for LPXN's inhibitory role in BCR signaling. Serial truncation and domain deletion mutagenesis, site-directed mutagenesis (Y72F, Y22F, Y198F, Y257F), overexpression in A20 B lymphoma cells, kinase assay, Co-immunoprecipitation, western blot, IL-2 ELISA The Journal of biological chemistry High 17640867
2006 LPXN associates with Src in osteoclasts; overexpression of LPXN in murine osteoclasts enhanced resorptive activity and cell adhesion; increased Pyk2 and Src co-immunoprecipitated with LPXN upon LPXN overexpression; TNF-alpha treatment further increased Src-LPXN association; LPXN scaffolds a podosomal signaling complex including Pyk2, PTP-PEST, and Src. Co-immunoprecipitation screen, in vitro resorption assay, cell adhesion assay, adenoviral overexpression American journal of physiology. Cell physiology Medium 16914530
2009 In an AML patient with t(11;21)(q12;q22), LPXN is fused to RUNX1 generating RUNX1/LPXN and LPXN/RUNX1 chimeric proteins; RUNX1/LPXN fusion proteins (RL, RLs) localize to the nucleus, recruit CBFB into the nucleus, and inhibit RUNX1-mediated transactivation of the CSF1R promoter; the LPXN/RUNX1 fusion (LR) localizes to the cytoplasm; wild-type LPXN and all fusion proteins confer NIH3T3 cells with malignant transformation (colony formation, tumor growth in nude mice). Fluorescence microscopy (localization), luciferase reporter assay (CSF1R promoter), co-immunoprecipitation (CBFB), soft agar colony assay, xenograft mouse model, RT-PCR Genes, chromosomes & cancer Medium 19760607
2009 LPXN overexpression in TRAMP prostate cancer mice enhanced PCa progression and metastasis; LPXN overexpression downregulates p120catenin (p120CTN) expression, causing nuclear accumulation of beta-catenin and increased MMP-7 transcription; siRNA knockdown of LPXN restored membranous beta-catenin localization; p120CTN knockdown phenocopied LPXN overexpression with nuclear beta-catenin accumulation. Transgenic mouse model (LPXN/TRAMP double transgenic), siRNA knockdown, immunofluorescence, western blot, luciferase reporter (MMP-7 promoter), in vitro migration/invasion assay Oncogene High 19701244
2010 LIM3 domain is the primary focal adhesion (FA) targeting domain for LPXN; bombesin/GRPr activation stimulates LPXN translocation from cytoplasm to FAs and induces tyrosine phosphorylation at Y22, Y62, and Y72; a LIM3 point mutant fails to target FAs and shows no BN-stimulated phosphorylation; the non-phosphorylatable Y22/62/72F mutant still translocates to FAs, demonstrating FA localization is required for phosphorylation but not vice versa; LPXN and paxillin have opposite roles in cell adhesion to collagen I — LPXN siRNA stimulates adhesion while paxillin siRNA inhibits it; LPXN regulates cell spreading on collagen I but not fibronectin. Mutagenesis (LIM3 point mutant, Y22/62/72F), siRNA knockdown, live-cell imaging/immunofluorescence, cell adhesion assay, cell spreading assay, bombesin stimulation Cell adhesion & migration High 20543562
2015 LPXN interacts with the actin-binding protein caldesmon (CaD) in prostate cancer cells; this interaction is increased during migration; LPXN knockdown does not affect CaD expression but reduces CaD phosphorylation; LPXN promotes CaD phosphorylation by recruiting ERK; decreased CaD phosphorylation destabilizes CaD-F-actin affinity and enables cell motility; TAK1 expression is decreased after LPXN knockdown, placing TAK1 upstream in the LPXN-ERK-CaD axis. Co-immunoprecipitation, siRNA knockdown, antibody array, western blot, in vitro migration/invasion assay Oncotarget Medium 26079947
2015 ETV6-LPXN fusion transcript (ETV6 exon 4 fused to LPXN exon 2) arises from t(11;12)(q12.1;p13) in relapsing AML; ETV6-LPXN does not confer IL-3 independence in 32D cells but enhances proliferative response to G-CSF without blocking granulocytic differentiation; 32D and human leukemia cell lines expressing ETV6-LPXN show enhanced migration toward CXCL12. 3'-RACE PCR, FISH, retroviral transduction of 32D cells, proliferation assay, Transwell migration assay (CXCL12 chemotaxis) Genes, chromosomes & cancer Medium 26542893
2020 Kindlin-3 directly interacts with LPXN (and paxillin) via G43/L47 within its F0 domain, as determined by NMR spectroscopy; disruption of Kindlin-3-PXN/LPXN interactions in Raw 264.7 macrophages promoted cell spreading, polarization, general motility, directed migration, transition from mesenchymal to amoeboid movement, and augmented phagocytosis — in contrast to the defects seen with Kindlin-3 knockout — indicating that the Kindlin-3–LPXN/PXN link limits myeloid cell motility and phagocytosis. NMR spectroscopy, mutagenesis (G43/L47 disruption), macrophage functional assays (spreading, migration, phagocytosis), genetic loss-of-function comparison Journal of immunology High 32094207
2022 PTK2B (Pyk2) phosphorylates LPXN in FLT3-mutated AML cells undergoing TKI resistance; LPXN and PTK2B are co-induced during early TKI resistance development; PTK2B/FAK inhibition abrogates resistance-associated phenotypes including enhanced cell migration; LPXN and PTK2B are highly expressed in leukemic stem cells from FLT3-ITD patients. Multilayered proteome analysis, nascent proteomics, PTK2B/FAK pharmacological inhibition, xenograft mouse model, cell migration assay Leukemia Medium 36056084
2017 LPXN overexpression in THP-1 cells (human acute monocytic leukemia) promotes proliferation via ERK upregulation, promotes adhesion to fibronectin via upregulation of integrin α4/β1 and α5/β1 complexes, and promotes invasion via MMP-2 activation. Lentiviral overexpression, CCK-8 proliferation assay, adhesion assay, Transwell invasion assay, western blot, gelatin zymography Zhongguo shi yan xue ye xue za zhi Low 28641616
2018 In SHI-1 acute monocytic leukemia cells, siRNA-mediated LPXN knockdown inhibits proliferation, decreases transmembrane invasion, reduces MMP-2 and MMP-9 secretion, and activates p38 MAPK and JNK signaling, but does not affect p-ERK levels, placing LPXN upstream of JNK/p38 MAPK and MMP-2/9 in this context. siRNA transfection, CCK-8 proliferation assay, Transwell invasion assay, western blot, gelatin zymography Oncology letters Low 30655748
2018 LPXN promotes bladder cancer cell proliferation, invasion, and angiogenesis; these effects are abolished by PI3K/AKT pathway inhibition; LPXN upregulates S100P expression via the PI3K/AKT pathway. Overexpression and siRNA knockdown, western blot, PI3K/AKT inhibitor treatment, in vitro and in vivo functional assays Cellular physiology and biochemistry Low 29975926
2023 LPXN and Hic-5 (paxillin family members) stabilize the lipid droplet-associated protein CIDEC by reducing its ubiquitination and inhibiting proteasomal degradation, thereby enlarging lipid droplets and promoting lipid storage in adipocytes; this effect is independent of triacylglycerol synthesis and FAK signaling pathways. HTRF-based high-throughput screening, co-immunoprecipitation, ubiquitination assay, proteasome inhibitor treatment, lipid droplet imaging, adipocyte functional assay The Journal of biological chemistry Medium 38159847
2024 LPXN acts as a coactivator for HNF4α to regulate hepatic gluconeogenesis; LPXN interacts with HNF4α (identified by pull-down and mass spectrometry); LPXN translocates into the nucleus and binds the PEPCK promoter (confirmed by CUT&Tag and ChIP-qPCR); LPXN-mediated regulation of gluconeogenesis proceeds mainly through the Gcg-cAMP-PKA pathway; liver-specific knockdown of LPXN enhances glucose metabolism, while overexpression inhibits it in mice and primary hepatocytes. Protein pull-down, mass spectrometry, luciferase reporter assay, CUT&Tag, ChIP-qPCR, adenoviral overexpression and AAV-shRNA knockdown in vivo (ob/db/DIO mice), primary hepatocyte culture Molecular metabolism High 39603504
2025 HLF transcription factor (epigenetically silenced by BRG1/SWI/SNF) negatively regulates LPXN expression; HLF depletion upregulates LPXN, which modulates integration of collagen mechanical cues with the actin cytoskeleton through Paxillin, thereby promoting cancer cell migration and lung metastasis; HLF overexpression abrogates these effects. In vivo CRISPR-Cas9 genome-wide screen, overexpression and knockdown (HLF, LPXN), cell migration assay (collagen), xenograft lung metastasis model Nature communications Medium 40473600
2025 LPXN promotes breast cancer progression by enhancing macrophage M2 polarization through a LPXN/HDAC6/EGR2 axis: LPXN overexpression in breast cancer correlates with M2 macrophage markers; siRNA silencing of LPXN in macrophages reduces HDAC6 expression; HDAC6 interacts with EGR2 and functions as its deacetylase, negatively regulating EGR2 expression; HDAC6 inhibition partially reverses pro-M2 effects of LPXN overexpression; EGR2 silencing attenuates the anti-M2 effects of LPXN knockdown. siRNA silencing, co-culture (breast cancer cells + macrophages), western blot, co-immunoprecipitation (HDAC6-EGR2), HDAC6 inhibitor treatment, murine breast cancer model Cell biology and toxicology Low 41286384
2020 Lpxn deficiency in mice leads to decreased B cell differentiation into plasma cells in vitro, but Lpxn is dispensable for T-dependent and T-independent B cell immune responses in vivo, indicating that in vivo BCR signaling can proceed normally without Lpxn. Lpxn knockout mouse model, in vitro B cell differentiation assay, in vivo immunization (T-dependent and T-independent antigens), ELISA for antibody titers Frontiers in immunology Medium 32269569

Source papers

Stage 0 corpus · 39 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2011 Identification of NDRG1-regulated genes associated with invasive potential in cervical and ovarian cancer cells. Biochemical and biophysical research communications 43 21463610
2013 Susceptibility loci associated with specific and shared subtypes of lymphoid malignancies. PLoS genetics 41 23349640
2007 Interaction of Pyk2 and PTP-PEST with leupaxin in prostate cancer cells. American journal of physiology. Cell physiology 37 17329398
2018 Leupaxin Promotes Bladder Cancer Proliferation, Metastasis, and Angiogenesis Through the PI3K/AKT Pathway. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 27 29975926
2010 Leupaxin is similar to paxillin in focal adhesion targeting and tyrosine phosphorylation but has distinct roles in cell adhesion and spreading. Cell adhesion & migration 24 20543562
2015 Leupaxin stimulates adhesion and migration of prostate cancer cells through modulation of the phosphorylation status of the actin-binding protein caldesmon. Oncotarget 23 26079947
2007 Leupaxin negatively regulates B cell receptor signaling. The Journal of biological chemistry 23 17640867
2021 Exogenous extracellular matrix proteins decrease cardiac fibroblast activation in stiffening microenvironment through CAPG. Journal of molecular and cellular cardiology 22 34118218
2018 Acute myeloid leukemia carrying ETV6 mutations: biologic and clinical features. Hematology (Amsterdam, Netherlands) 21 29894279
2020 Macrophage Migration and Phagocytosis Are Controlled by Kindlin-3's Link to the Cytoskeleton. Journal of immunology (Baltimore, Md. : 1950) 20 32094207
2020 Clinicopathological Significances of Cancer Stem Cell-Associated HHEX Expression in Breast Cancer. Frontiers in cell and developmental biology 17 33425911
2006 Association of leupaxin with Src in osteoclasts. American journal of physiology. Cell physiology 16 16914530
2022 Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML. Leukemia 15 36056084
2021 Epigenetic adaptations of the masticatory mucosa to periodontal inflammation. Clinical epigenetics 13 34732256
2015 ETV6-LPXN fusion transcript generated by t(11;12)(q12.1;p13) in a patient with relapsing acute myeloid leukemia with NUP98-HOXA9. Genes, chromosomes & cancer 11 26542893
2009 LPXN, a member of the paxillin superfamily, is fused to RUNX1 in an acute myeloid leukemia patient with a t(11;21)(q12;q22) translocation. Genes, chromosomes & cancer 11 19760607
2009 Leupaxin acts as a mediator in prostate carcinoma progression through deregulation of p120catenin expression. Oncogene 10 19701244
2025 Chemical Probe-Enabled Lipid Droplet Proteomics. Journal of the American Chemical Society 9 40069114
2022 A protein coupling and molecular simulation analysis of the clinical mutants of androgen receptor revealed a higher binding for Leupaxin, to increase the prostate cancer invasion and motility. Computers in biology and medicine 9 35504219
2020 The molecular basis of gender disparities in smoking lung cancer patients. Life sciences 8 33358908
2025 Transcriptomic Signatures in TP53 Positive and Negative Tumor Samples in NSCLC. Current gene therapy 6 40798960
2024 STAT3 mediates ECM stiffness-dependent progression in ovarian cancer. Molecular and cellular biochemistry 6 38625514
2021 Dietary plant sterols prevented cholesterol gallstone formation in mice. Food & function 6 34787152
2020 Leupaxin Expression Is Dispensable for B Cell Immune Responses. Frontiers in immunology 6 32269569
2023 Paxillin family proteins Hic-5 and LPXN promote lipid storage by regulating the ubiquitination degradation of CIDEC. The Journal of biological chemistry 4 38159847
2018 Downregulation of LPXN expression by siRNA decreases the malignant proliferation and transmembrane invasion of SHI-1 cells. Oncology letters 4 30655748
2025 SWI/SNF ATPase silenced HLF potentiates lung metastasis in solid cancers. Nature communications 2 40473600
2013 [Molecular mechanisms of leupaxin involved in prostate carcinoma metastasis]. Zhonghua nan ke xue = National journal of andrology 2 23862238
2025 New Roles of Artemisinins in Atherosclerosis Progression. Phytotherapy research : PTR 1 40200587
2025 The Leupaxin/HDAC6/EGR2 axis facilitates breast cancer progression by enhancing macrophage M2 polarization. Cell biology and toxicology 1 41286384
2024 Characterization of a secondary hydroxy-acyltransferase for lipid A in Vibrio parahaemolyticus. Microbiological research 1 38593580
2024 Leupaxin promotes hepatic gluconeogenesis and glucose metabolism by coactivation with hepatic nuclear factor 4α. Molecular metabolism 1 39603504
2023 Nephroprotective potential of Polyalthia longifolia roots against vancomycin-induced renal toxicity in experimental animals. Frontiers in pharmacology 1 36755952
2017 [Effect of LPXN Overexpression on the Proliferation, Adhesion and Invasion of THP-1 Cells and Its Mechamisms]. Zhongguo shi yan xue ye xue za zhi 1 28641616
2012 [Tocilizumab impact on blood cholesterine transport and early manifestation of atherosclerosis in patients with rheumatoid arthritis]. Terapevticheskii arkhiv 1 22830205
2025 DNA methylation expression patterns predict outcome of clear cell renal cell carcinoma. Discover oncology 0 40419839
2025 An electroneutral fluorescent probe for visualization of lipid droplets polarity heterogeneity and NAFLD detection. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy 0 40882332
2018 [Small interfering RNA-mediated LPXN silencing suppresses proliferation and enhances drug sensitivity of human acute monocytic leukemia SHI-1 cells in vitro]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University 0 33168498
2013 [Low and very low density lipoproteins: pathogenetic and clinical significance]. Klinicheskaia meditsina 0 23659066

Missed literature

Know a paper Affinage missed for LPXN? Flag it for the maintainers and the community.

No submissions yet.